Our co-founder and CEO, Andrew Satz, recently gave a talk to data science students at the Flatiron School. He covered our work at EVQLV, our collaboration with ImmunoPrecise, and answered quite a number of questions. One of those question was a request to explain the meaning of the term the listeners had frequently heard thrown around: “In Silico.” Below is a clip of his response.

We also put together this short one-pager that demonstrates the value of In Silico drug design vis-a-vis In Vitro drug discovery.